GH-axis research
GHRP-2
Peptide di ricerca liofilizzato sulla segnalazione endocrina per la revisione dei sistemi
GHRP-2 is a growth hormone secretagogue research peptide studied around ghrelin-receptor activity and GH-release models.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesSolo per ricerca di laboratorio. Non per uso umano o veterinario. Non destinato a diagnosticare, trattare, curare, mitigare o prevenire malattie.
Conservare sigillato, freddo, asciutto e protetto dagli sbalzi di calore. Conferma lo stoccaggio specifico del prodotto all'arrivo.
Imballato per garantire la stabilità del transito con supporto per gli ordini disponibile per le rotte con clima caldo.
Batch-linked certificate support is available through the documentation desk.
Contesto di ricerca
Profilo di ricerca GHRP-2
GHRP-2 is a synthetic growth hormone secretagogue studied through the ghrelin receptor pathway. Research examines GH-release magnitude and timing, endocrine-response markers, receptor pharmacology, appetite-related observations, and comparisons with GHRP-6, ipamorelin, or GHRH analogs. Its experimental profile is not identical to ipamorelin, which is often studied for greater selectivity, or GHRP-6, which is frequently associated with stronger appetite-pathway observations. GHRP-2 is useful as an established secretagogue comparator in GH-axis work. Study design should separate direct GHS-R signaling from GHRH-receptor activity and should not translate endocrine findings into personal-use or treatment recommendations.
Molecular class
Six-residue GH secretagogue
Sequence / composition
D-Ala-D-beta-naphthylalanine-Ala-Trp-D-Phe-Lys-NH2; a short peptide with D-amino-acid substitutions.
Research design note
Its non-natural residues are part of the GHS-R pharmacology and should be distinguished from a native ghrelin sequence.
Meccanismo proposto
A synthetic agonist at GHS-R1a. It stimulates pituitary growth-hormone release and also engages hypothalamic ghrelin-related pathways; endocrine selectivity is lower than that reported for ipamorelin.
Effetti riportati negli studi
- Human studies reported marked acute GH release, with responses influenced by dose, age, nutrition, and concurrent GHRH signaling.
- Studies also reported appetite-related effects and changes in ACTH, cortisol, or prolactin under some conditions.
- Repeated exposure can produce altered responsiveness or desensitization depending on the experimental schedule.
Endpoint di ricerca comuni
GHS-R potency, GH peak and area under the curve, ACTH, cortisol, prolactin, food intake, glucose, receptor desensitization, and synergy experiments with GHRH.
Evidenze e limiti
Human endocrine pharmacology and preclinical evidence exist, but long-term effects and catalog-product equivalence are not established.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
Where can I find product documentation?
Contact support with the product name and any relevant order or batch reference to request available documents.
How can I compare pack options?
Where multiple pack sizes are available, Azure shows the price per listed vial so you can compare catalog value directly.